AstraZeneca PLC (LON: AZN)
London
· Delayed Price · Currency is GBP · Price in GBX
10,436
+14 (0.13%)
Dec 24, 2024, 12:35 PM BST
AstraZeneca Revenue
AstraZeneca had revenue of $13.57B USD in the quarter ending September 30, 2024, with 18.04% growth. This brings the company's revenue in the last twelve months to $51.21B, up 13.81% year-over-year. In the year 2023, AstraZeneca had annual revenue of $45.81B with 3.29% growth.
Revenue (ttm)
$51.21B
Revenue Growth
+13.81%
P/S Ratio
4.23
Revenue / Employee
$569.59K
Employees
89,900
Market Cap
161.57B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 45.81B | 1.46B | 3.29% |
Dec 31, 2022 | 44.35B | 6.93B | 18.53% |
Dec 31, 2021 | 37.42B | 10.80B | 40.58% |
Dec 31, 2020 | 26.62B | 2.23B | 9.16% |
Dec 31, 2019 | 24.38B | 2.29B | 10.38% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
GSK plc | 31.31B |
Haleon plc | 11.24B |
Smith & Nephew plc | 4.46B |
ConvaTec Group PLC | 1.74B |
Hikma Pharmaceuticals PLC | 2.39B |
Oxford Nanopore Technologies plc | 167.75M |
Animalcare Group plc | 76.10M |
AstraZeneca News
- 5 hours ago - AstraZeneca withdraws application for lung cancer drug in EU - Reuters
- 6 hours ago - Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn - Business Wire
- 15 hours ago - AstraZeneca PLC Investors: Please contact the Portnoy Law Firm to recover your losses; February 21, 2025 Deadline to file Lead Plaintiff Motion - GlobeNewsWire
- 15 hours ago - AZN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that AstraZeneca PLC Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Accesswire
- 15 hours ago - AZN INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that AstraZeneca PLC Investors with Substantial Losses Have Opportunity to Lead the AstraZeneca Class Action Lawsuit - GlobeNewsWire
- 17 hours ago - EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of AstraZeneca PLC Investors – AZN - Business Wire
- 20 hours ago - AstraZeneca gets EU okay for Tagrisso for EGFR lung cancer - Seeking Alpha
- 1 day ago - EU Approves AstraZeneca's (AZN) Tagrisso for Advanced Lung Cancer Treatment - GuruFocus